Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsMiguel Sanmamed, MD, PhD
Assistant Professor AdjunctAbout
Research
Publications
2026
Safety, feasibility and pharmacodynamic activity of intratumoral injections of the agonist anti-CD137 (4-1BB) mAb urelumab in combination with nivolumab.
Sanmamed M, de Andrea C, Ruiz-Guillamón D, Rodriguez-Ruiz M, Ortego I, Eguren-Santamaría I, Benito A, López-Janeiro A, Gonzalez Gomariz J, Villalba-Esparza M, Molina A, Krasko A, Ponz-Sarvise M, Lopez-Picazo J, Gomis G, Molero-Glez P, Alexandru R, Pérez-Domínguez P, Rodriguez I, Sánchez-Gregorio S, Perez-Gracia J, Melero I. Safety, feasibility and pharmacodynamic activity of intratumoral injections of the agonist anti-CD137 (4-1BB) mAb urelumab in combination with nivolumab. Clinical Cancer Research 2026 PMID: 41543348, DOI: 10.1158/1078-0432.ccr-25-2502.Peer-Reviewed Original Research
2025
Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic
Eguren-Santamaria I, Melero I, Rodríguez I, Ortego I, Armero M, Galvez-Cancino F, López-Janeiro A, De Andrea C, Sanmamed M. Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic. Journal For ImmunoTherapy Of Cancer 2025, 13: e011279. PMID: 41161818, PMCID: PMC12574409, DOI: 10.1136/jitc-2024-011279.Peer-Reviewed Original ResearchConceptsHumanized mouse modelMouse modelImmunotherapy agentsClinical trialsHuman cancersFeatures of human cancersCancer immunotherapy applicationsPreclinical experimental modelsIn vivo modelsImmunotherapy interventionsPreclinical modelsPreclinical resultsClinical failureImmune cellsClinical developmentImmunotherapyImmunotherapy applicationsAnticancer treatmentHuman tumorsTherapeutic strategiesPreclinical researchEx vivoHuman specimensCancerExperimental modelBrief Report: Emphysema as a prognostic factor in advanced NSCLC patients with COPD receiving immune checkpoint inhibitors.
Di Frisco M, Sanmamed M, Ferrández J, Vilalta A, Sogbe M, García-Goñi M, Martin-Palmero Á, Aso-González S, Nadal E, Signes-Costa J, Gambardella V, Seguí Manzaneque V, Martin P, Insa A, Franco J, Lores C, de Torres J. Brief Report: Emphysema as a prognostic factor in advanced NSCLC patients with COPD receiving immune checkpoint inhibitors. Journal Of Thoracic Oncology 2025 PMID: 41130410, DOI: 10.1016/j.jtho.2025.10.007.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsChronic obstructive pulmonary diseaseAdvanced NSCLCChest Computed TomographyOverall survivalCheckpoint inhibitorsPrognostic factorsNSCLC treated with immune checkpoint inhibitorsSingle-agent immune checkpoint inhibitorsAssociated with longer overall survivalAdvanced NSCLC patientsProgression-free survivalSecond-line treatmentLonger overall survivalAdverse event ratesLung cancer developmentObstructive pulmonary diseaseEmphysema statusNSCLC patientsPrognostic markerMultivariate analysisCancer developmentPulmonary diseasePatientsRisk factorsAssociation of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients
de Andrea C, Abengozar-Muela M, Arranz J, Climent M, Puente J, Vizcay Á, de la Fuente L, Jurado J, Bonfill T, Santander C, Villa J, Pujol E, Rosero A, Gomez J, Fernández E, Fernández C, Ramirez I, Arnáiz P, López-Janeiro Á, Melero I, Sanmamed M, Pérez-Gracia J. Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients. OncoImmunology 2025, 14: 2538687. PMID: 40778981, DOI: 10.1080/2162402x.2025.2538687.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntigens, CDBiomarkers, TumorCD8-Positive T-LymphocytesFemaleHepatitis A Virus Cellular Receptor 2HumansLymphocyte Activation Gene 3 ProteinMaleMiddle AgedProgrammed Cell Death 1 ReceptorTumor MicroenvironmentUrinary Bladder NeoplasmsConceptsAdvanced urothelial cancerMultiplexed quantitative immunofluorescenceTumor microenvironmentT cellsClinical efficacyPD-1LAG-3Tim-3Urothelial cancerPredictive biomarkersReal-world evidenceDistribution of CD8+ T cellsQuantitative immunofluorescenceCD8+ T-cell densityAdvanced urothelial carcinoma patientsAssociation of PD-1Intratumoral CD8 T cellsPatients treated with atezolizumabPre-treatment tumor samplesCD8+ T cellsPD-1/PD-L1 pathwayHundred-nine patientsPD-L1 blockadeResponse to atezolizumabCD8 T cellsDasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy.
Redin E, Otegui N, Santos M, Leon S, Redrado M, Serrano D, Fernandez de Pierola E, Russo-Cabrera J, Ferrer I, Olmedo M, Diaz-Lagares A, Houry M, Vicent S, Vilalta A, Mondelo-Macía P, García-González J, León-Mateos L, Gonzalez A, Paz-Ares L, López R, Sanmamed M, Montuenga L, Calvo A. Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy. Cancer Research 2025, 85: 3910-3929. PMID: 40712061, DOI: 10.1158/0008-5472.can-24-2772.Peer-Reviewed Original ResearchSmall cell lung cancerAntigen presenting cellsAnti-PD-1Cell lung cancerT cellsTumor infiltrationNatural killerNK cellsAntitumor efficacyLung cancerReduction of regulatory T cellsLonger progression-free survivalInfiltration of CD4+CD8+ T cellsCD4+ T cellsSmall cell lung cancer modelSmall cell lung cancer cellsTreg cell conversionImmune checkpoint blockadeAssociated with poor prognosisProgression-free survivalImmunotherapy-treated patientsTumor mutational burdenRegulatory T cellsCD4+ lymphocytesErratum: BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203
Márquez-Rodas I, Dutriaux C, Saiag P, de la Cruz Merino L, Castañón Álvarez E, Robert C, Rodríguez-Moreno J, Arance A, Cerezuela-Fuentes P, Montaudié H, Sanmamed M, González-Cao M, Charles J, López Criado M, Berrocal A, de Miguel E, Funck-Brentano E, Prey S, Álamo de la Gala M, Melero I, Avilés-Izquierdo J, Roman R, Garcia-Pelaez B, Rodriguez S, Trnkova Z, Quintero M, Maciá S, Chaney M, Dalle S. Erratum: BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203. Journal Of Clinical Oncology 2025, 43: 2840-2840. PMID: 40706004, DOI: 10.1200/jco-25-01680.Peer-Reviewed Original ResearchPhase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas
Wermke M, Gambardella V, Kuboki Y, Felip E, Sanmamed M, Alese O, Sayehli C, Arriola E, Wolf J, Villaruz L, Bertulis J, Studeny M, Bouzaggou M, Fang X, Morgensztern D. Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas. Journal Of Clinical Oncology 2025, 43: 3021-3031. PMID: 40706016, PMCID: PMC12440289, DOI: 10.1200/jco-25-00363.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerMaximum tolerated doseOverall response rateStep-up dosingCell lung cancerNeuroendocrine carcinomaFixed doseTarget doseAnti-PD-1/PD-L1 therapyLung cancerTreatment-related adverse eventsExtrapulmonary neuroendocrine carcinomasCell neuroendocrine carcinomaDose-limiting toxicityT-cell engagersCytokine release syndromeMinimum effective doseRECIST v1.1Tumor responseMedian durationTumor typesAdverse eventsDose onceRegimensAnticancer therapyLifileucel tumor‐infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors
Kluger H, Grigoleit G, Thomas S, Domingo‐Musibay E, Chesney J, Sanmamed M, Medina T, Ziemer M, Whitman E, Finckenstein F, Gastman B, Chou J, Wu X, Sulur G, Fiaz R, Qi R, Sarnaik A. Lifileucel tumor‐infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors. Cancer Communications 2025, 45: 1229-1234. PMID: 40693376, PMCID: PMC12531414, DOI: 10.1002/cac2.70050.Peer-Reviewed Original ResearchBO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203
Márquez-Rodas I, Dutriaux C, Saiag P, de la Cruz Merino L, Álvarez E, Robert C, Rodríguez-Moreno J, Arance A, Cerezuela-Fuentes P, Montaudié H, Sanmamed M, González-Cao M, Charles J, Criado M, Berrocal A, de Miguel E, Funck-Brentano E, Prey S, de la Gala M, Melero I, Avilés-Izquierdo J, Roman R, Garcia-Pelaez B, Rodriguez S, Trnkova Z, Quintero M, Maciá S, Chaney M, Dalle S. BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203. Journal Of Clinical Oncology 2025, 43: 2806-2815. PMID: 40577656, PMCID: PMC12393066, DOI: 10.1200/jco-24-02595.Peer-Reviewed Original ResearchConceptsProgression-free survivalDuration of responsePhase II clinical trialBO-112Primary end pointOverall survivalEnd pointsClinical trialsAnti-PD-1 resistanceMedian duration of responseMedian progression-free survivalProgression-free survival resultsNo deaths related to treatmentIntention-to-treat populationDeaths related to treatmentAnti-PD-1Central radiology reviewIntravenous pembrolizumabStable diseaseAdvanced melanomaProgressive diseaseRadiological reviewSolid tumorsPembrolizumabAdverse eventsEfficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial.
Capdevila J, Gambardella V, Kuboki Y, Alese O, Morgensztern D, Sayehli C, Sanmamed M, Arriola E, Studeny M, Bouzaggou M, Chen Z, Lifke V, Wolf J, Wermke M. Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial. Journal Of Clinical Oncology 2025, 43: 3004-3004. DOI: 10.1200/jco.2025.43.16_suppl.3004.Peer-Reviewed Original ResearchDelta-like ligand 3Disease control rateExtrapulmonary neuroendocrine carcinomasNeuroendocrine carcinomaMedian DORDose escalationImmune effector cell-associated neurotoxicity syndromeDose-escalation regimensDose-escalation trialDuration of responseT-cell engagersCytokine release syndromePhase I trialRECIST v1.1Systemic therapyI trialBaseline characteristicsNeurotoxicity syndromeSafety profileStandard treatmentControl rateTumor cellsEfficacy dataDisease progressionResponse rate